Clinical Trials Browser

Withdrawn × INDUSTRY × Hematologic Neoplasms × Clear all

Hematologic Neoplasms

NCT05061654 2023-08-14

CEF-10

Phase 4 Withdrawn

Classical hematologyOther hematologic neoplasm

Hematologic Neoplasms, Febrile Neutropenia

NCT01792882 2023-02-28

GBCPRT0008

Withdrawn

BreastGastrointestinalGenitourinaryOther hematologic neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT04464889 2021-10-08

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02223312 2018-08-28

Therapy for Progressive and/or Refractory Hematologic Malignancies

Phase 1/2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Withdrawn

OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

NCT01168882 2012-08-02

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Phase 1 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Clinical Trials

ARIA

CEF-10

GBCPRT0008

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Therapy for Progressive and/or Refractory Hematologic Malignancies

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies